In today’s recent session, 0.73 million shares of the Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) have been traded, and its beta is 0.52. Most recently the company’s share price was $0.72, and it changed around -$0.11 or -13.10% from the last close, which brings the market valuation of the company to $1.55M. CYCC at last check was trading at a discount to its 52-week high of $10.12, offering almost -1305.56% off that amount. The share price’s 52-week low was $0.75, which indicates that the recent value has fallen by an impressive -4.17% since then. We note from Cyclacel Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 6.04 million shares, with the 3-month average coming to 974.56K.
Cyclacel Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 2.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended CYCC as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Cyclacel Pharmaceuticals Inc is expected to report earnings per share of -0.55 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) trade information
Instantly CYCC has been showing red trend so far today with a performance of -13.10% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.4900 on recent trading dayincreased the stock’s daily price by 71.08%. The company’s shares are currently down -72.92% year-to-date, but still down -45.23% over the last five days. On the other hand, Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) is -29.81% down in the 30-day period. We can see from the shorts that 36495.0 shares have been sold at a short interest cover period of 1.1 day(s).
The consensus price target as assigned by Wall Street analysts is $1, which translates to bulls needing to increase their stock price by 28.0% from its current value. Analyst projections state that CYCC is forecast to be at a low of $1 and a high of $1.
Cyclacel Pharmaceuticals Inc (CYCC) estimates and forecasts
Cyclacel Pharmaceuticals Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -46.84 percent over the past six months and at a 91.44% annual growth rate that is well above the industry average of 17.50%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 92.50% in revenue this quarter, and will report an increase of 93.60% in the next quarter. The year-over-year growth rate is expected to be -90.50%, down from the previous year.
The company’s sales for the same quarters a year ago were 16k and 31k respectively.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 32.13%.
CYCC Dividends
Cyclacel Pharmaceuticals Inc’s next quarterly earnings report is expected to be released on 2024-Nov-11.
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 4.82% of Cyclacel Pharmaceuticals Inc shares, and 18.03% of them are in the hands of institutional investors. The stock currently has a share float of 18.94%.
